Akshaya Keerti/LinkedIn
Apr 26, 2025, 13:55
Akshaya Keerti: I’ve always been a strong advocate of ADC shaping up the new treatment regimen and improving patient outcome
Akshaya Keerti, International Council Deputy Director at Federation of Medical Students Association (FMSA), shared on LinkedIn:
“Great news!
DESTINY-Breast09 results are out! Primary endpoint (PFS) met! Congrats to all the patients and Dr Sarah Tonaley (PI) and AstraZeneca. Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.
I’ve always been a strong advocate of ADC shaping up the new treatment regimen and improving patient outcome. One step further into the future of having better care of the Her2positive patients to improve their prognosis. Looking forward to conducting similar trials in LMIC like India in the near future.”
See other posts featuring Akshaya Keerti on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 26, 2025, 13:26
Apr 26, 2025, 12:58
Apr 26, 2025, 12:39